Search

Displaying results 1521 - 1530 of 7604 in total
  1. Drug

    Estradiol

    go.drugbank.com/drugs/DB00783
    ApprovedInvestigationalVet approved

    Ethinyl estradiol is different from estradiol due to its higher biovailability and increased resistance to metabolism, rendering it more suitable for oral administration. … Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain.

    Mixtures: KLIOGEST N, KLIOGEST NProducts: ESTRAMON UNO 50, ESTRAMON UNO 75
  2. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain … serves to limit associated toxicities.

  3. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development … Vosoritide is an analog of CNP with proline-glycine on its N-terminus to convey resistance to neutral endopeptidase.

  4. Drug

    Factor XIII (human)

    go.drugbank.com/drugs/DB12909
    ApprovedInvestigational

    When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical

  5. Drug

    Human calcitonin

    go.drugbank.com/drugs/DB06773
    Approved

    Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calci...

  6. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure … These modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation.

  7. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries … [L64095] It blocks neuromuscular transmission by cleaving SNAP-25, producing partial chemical denervation and a localized reduction in muscle activity.

  8. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  9. Drug

    Cefazolin

    go.drugbank.com/drugs/DB01327
    ApprovedInvestigational

    A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

  10. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816] … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.